Posted by Michael Wonder on 30 Jul 2024
AffyImmune receives FDA regenerative medicine advanced therapy designation for AIC100 in recurrent anaplastic thyroid cancer
23 July 2024 - RMAT designation follows FDA’s review of available preliminary clinical evidence that AIC100 has the potential to address unmet medical need in recurrent anaplastic thyroid cancer.
AffyImmune announced today the designation of regenerative medicine advanced therapy by the US FDA for its CAR T-cell product candidate, AIC100 as a potential treatment for patients with recurrent anaplastic thyroid cancer, the most aggressive form of the disease.
